Loading...

DBV Technologies

ENXTPA:DBV
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DBV
ENXTPA
€607M
Market Cap
  1. Home
  2. FR
  3. Pharmaceuticals & Biotech
Company description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • DBV Technologies has significant price volatility in the past 3 months.
DBV Share Price and Events
7 Day Returns
4.5%
ENXTPA:DBV
1.5%
FR Biotechs
1.9%
FR Market
1 Year Returns
-60%
ENXTPA:DBV
-33.5%
FR Biotechs
-2.3%
FR Market
DBV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DBV Technologies (DBV) 4.5% 8% 28.5% -60% -68.7% -10.2%
FR Biotechs 1.5% -2.5% 2.9% -33.5% -50.4% -32.4%
FR Market 1.9% -2.3% 5.9% -2.3% 30.8% 29.8%
1 Year Return vs Industry and Market
  • DBV underperformed the Biotechs industry which returned -33.5% over the past year.
  • DBV underperformed the Market in France which returned -2.3% over the past year.
Price Volatility
DBV
Industry
5yr Volatility vs Market
Related Companies

DBV Value

 Is DBV Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for DBV Technologies. This is due to cash flow or dividend data being unavailable. The share price is €16.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DBV Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DBV Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTPA:DBV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-5.74
ENXTPA:DBV Share Price ** ENXTPA (2019-05-17) in EUR €16.82
France Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 18.19x
France Market PE Ratio Median Figure of 418 Publicly-Listed Companies 17.81x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DBV Technologies.

ENXTPA:DBV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:DBV Share Price ÷ EPS (both in EUR)

= 16.82 ÷ -5.74

-2.93x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DBV Technologies is loss making, we can't compare its value to the FR Biotechs industry average.
  • DBV Technologies is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does DBV Technologies's expected growth come at a high price?
Raw Data
ENXTPA:DBV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.93x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
37.3%per year
France Biotechs Industry PEG Ratio Median Figure of 7 Publicly-Listed Biotechs Companies 0.34x
France Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for DBV Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on DBV Technologies's assets?
Raw Data
ENXTPA:DBV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €4.03
ENXTPA:DBV Share Price * ENXTPA (2019-05-17) in EUR €16.82
France Biotechs Industry PB Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 2.33x
France Market PB Ratio Median Figure of 619 Publicly-Listed Companies 1.44x
ENXTPA:DBV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:DBV Share Price ÷ Book Value per Share (both in EUR)

= 16.82 ÷ 4.03

4.18x

* Primary Listing of DBV Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DBV Technologies is overvalued based on assets compared to the FR Biotechs industry average.
X
Value checks
We assess DBV Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. DBV Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DBV Future Performance

 How is DBV Technologies expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DBV Technologies expected to grow at an attractive rate?
  • DBV Technologies's earnings growth is expected to exceed the low risk savings rate of 0.7%.
Growth vs Market Checks
  • DBV Technologies's earnings growth is expected to exceed the France market average.
  • DBV Technologies's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
Raw Data
ENXTPA:DBV Future Growth Rates Data Sources
Data Point Source Value (per year)
ENXTPA:DBV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 37.3%
ENXTPA:DBV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 49.6%
France Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 32.7%
France Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 39.4%
France Market Earnings Growth Rate Market Cap Weighted Average 13.2%
France Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTPA:DBV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTPA:DBV Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 422 141 85 2
2022-12-31 220 6 -6 2
2021-12-31 116 -74 -106 2
2020-12-31 14 -175 -165 4
2019-12-31 15 -146 -174 4
ENXTPA:DBV Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 11 -137 -166
2018-09-30 10 -130 -157
2018-06-30 9 -124 -147
2018-03-31 9 -119 -147
2017-12-31 10 -114 -148
2017-09-30 10 -100 -143
2017-06-30 9 -85 -138
2017-03-31 9 -72 -126
2016-12-31 8 -60 -115
2016-09-30 7 -52 -97
2016-06-30 7 -44 -80
2016-03-31 7 -36 -63

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • DBV Technologies's earnings are expected to grow significantly at over 20% yearly.
  • DBV Technologies's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTPA:DBV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from DBV Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:DBV Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 -3.13 -1.25 -4.88 3.00
2020-12-31 -5.13 -2.88 -7.78 4.00
2019-12-31 -5.48 -3.93 -6.78 4.00
ENXTPA:DBV Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31 -5.74
2018-09-30 -5.68
2018-06-30 -5.60
2018-03-31 -5.78
2017-12-31 -5.97
2017-09-30 -5.78
2017-06-30 -5.59
2017-03-31 -5.14
2016-12-31 -4.68
2016-09-30 -4.01
2016-06-30 -3.33
2016-03-31 -2.78

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if DBV Technologies will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess DBV Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DBV Technologies has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DBV Past Performance

  How has DBV Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DBV Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DBV Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare DBV Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare DBV Technologies's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
DBV Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DBV Technologies Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTPA:DBV Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 11.19 -166.08 76.30 104.47
2018-09-30 10.12 -156.65 67.31 102.57
2018-06-30 9.05 -147.23 58.32 100.67
2018-03-31 9.32 -147.46 56.00 101.94
2017-12-31 9.60 -147.69 53.69 103.21
2017-09-30 9.55 -142.66 53.45 100.53
2017-06-30 9.49 -137.63 53.21 95.19
2017-03-31 8.51 -126.08 50.71 85.39
2016-12-31 7.53 -114.53 48.20 76.93
2016-09-30 7.48 -97.09 41.55 64.22
2016-06-30 7.43 -79.64 34.90 52.84
2016-03-31 6.93 -63.26 27.08 43.68
2015-12-31 6.17 -44.67 18.45 33.06
2015-09-30 5.72 -35.70 14.23 27.86
2015-06-30 5.27 -26.72 9.70 22.70
2015-03-31 4.94 -24.93 8.02 22.43
2014-12-31 4.76 -24.01 8.39 20.87
2014-09-30 4.96 -23.59 7.87 21.07
2014-06-30 5.15 -23.17 8.03 20.73
2014-03-31 4.44 -20.56 7.97 17.55
2013-12-31 3.83 -19.31 6.31 17.37
2013-09-30 3.31 -17.35 6.17 15.04
2013-06-30 2.80 -15.39 5.77 12.98
2013-03-31 2.79 -14.15 5.31 12.11
2012-12-31 2.78 -12.91 4.86 11.24
2012-09-30 2.52 -11.29 4.15 9.94
2012-06-30 2.25 -9.57 3.54 8.43

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if DBV Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if DBV Technologies has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if DBV Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess DBV Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DBV Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DBV Health

 How is DBV Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DBV Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DBV Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DBV Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of DBV Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 58.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DBV Technologies Company Filings, last reported 4 months ago.

ENXTPA:DBV Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 121.29 2.48 122.77
2018-09-30 121.29 2.48 122.77
2018-06-30 204.92 3.60 202.25
2018-03-31 204.92 3.60 202.25
2017-12-31 129.92 4.15 137.88
2017-09-30 129.92 4.15 137.88
2017-06-30 191.68 4.47 198.69
2017-03-31 191.68 4.47 198.69
2016-12-31 242.85 4.64 256.47
2016-09-30 242.85 4.64 256.47
2016-06-30 290.49 4.82 288.76
2016-03-31 290.49 4.82 288.76
2015-12-31 322.08 4.84 323.38
2015-09-30 322.08 4.84 323.38
2015-06-30 105.64 4.87 104.53
2015-03-31 111.60 4.92 110.31
2014-12-31 115.45 4.13 114.58
2014-09-30 115.45 4.13 114.58
2014-06-30 31.55 1.56 29.06
2014-03-31 40.39 1.44 39.40
2013-12-31 40.40 1.44 39.40
2013-09-30 40.39 1.44 39.40
2013-06-30 33.47 1.54 32.27
2013-03-31 33.47 1.54 32.27
2012-12-31 39.17 1.15 38.35
2012-09-30 39.17 1.15 38.35
2012-06-30 44.82 0.63 42.18
  • DBV Technologies's level of debt (2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (3.6% vs 2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • DBV Technologies has less than a year of cash runway based on current free cash flow.
  • DBV Technologies has less than a year of cash runway if free cash flow continues to grow at historical rates of 42% each year.
X
Financial health checks
We assess DBV Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DBV Technologies has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DBV Dividends

 What is DBV Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from DBV Technologies dividends. Estimated to be 0% next year.
If you bought €2,000 of DBV Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate DBV Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate DBV Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTPA:DBV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
France Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3.1%
France Minimum Threshold Dividend Yield 10th Percentile 1%
France Bottom 25% Dividend Yield 25th Percentile 1.6%
France Top 25% Dividend Yield 75th Percentile 4.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTPA:DBV Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as DBV Technologies has not reported any payouts.
  • Unable to verify if DBV Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of DBV Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as DBV Technologies has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of DBV Technologies's dividends in 3 years as they are not expected to pay a notable one for France.
X
Income/ dividend checks
We assess DBV Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DBV Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DBV Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DBV Management

 What is the CEO of DBV Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Daniel Tassé
AGE 58
TENURE AS CEO 0.5 years
CEO Bio

Mr. Daniel Tassé has been the Chief Executive Officer at DBV Technologies S.A. since November 29, 2018 and has been its Director since March 5, 2019. He served as the Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc. Mr. Tassé serves as Senior Advisor at Bridge Growth Partners, LLC. An accomplished healthcare executive, he has built and led businesses with global footprints in the fields of bio-pharmaceuticals, medical devices, diagnostics and health services. Prior to the acquisition of Ikaria by Mallinckrodt in April 2015, Mr. Tassé was President and Chief Executive Officer and Chairman of the Board of Ikaria and served as Interim Chief Executive Officer and President of Bellerophon Therapeutics, Inc. from February 2014 to June 2014. He has more than 35 years of biopharmaceutical leadership experience. He served as the Chairman of the Board of Ikaria, Inc. since October 2009 until 2015 and its Chief Executive Officer and President since January 2008 until April 2015. Mr. Tassé served as the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc. He served as President and Regional Director for Australasia at GlaxoSmithKline from 2001 to 2004. He held management positions at Upjohn. He had been Director at Bellerophon Therapeutics, Inc. from February 2014 until May 14, 2019. Mr. Tassé has been an Independent Director of Regenxbio Inc. since August 2016. Mr. Tassé has been an Independent Non-Executive Director of Indivior PLC since November 04, 2014 and has been its Senior Independent Director since September 30, 2016. He was an Independent Director of HLS Therapeutics Inc. He serves as a Member of Technology Advisory Board and Member of Strategic Advisory Board at Bridge Growth Partners, LLC. He has been Director of BioQ Pharma Incorporated since July 2015. He served as a Director and a Member of Health Section Governing Board at Biotechnology Innovation Organization from July 2011 to June 2015. He served as a Director of Ikaria Holdings, Inc. since January 2008 until April 2015. From 2011 to 2015, he served as a Board Director of PhRMA. He serves as the Chairman of the Foundation on National Critical Care Policy. He serves at the Sheikh Zayed Institute Business Advisory Council in DC. He is a board director of the Roundtable on Critical Care Policy. He was a Member of the Healthcare Leadership Council from 2010 to June 2015. Mr. Tassé holds a B.Sc. in Biochemistry from the University of Montreal and is fluent in both French and English.

CEO Compensation
  • Insufficient data for Daniel to compare compensation growth.
  • Insufficient data for Daniel to establish whether their remuneration is reasonable compared to companies of similar size in France.
Management Team Tenure

Average tenure and age of the DBV Technologies management team in years:

3
Average Tenure
54
Average Age
  • The tenure for the DBV Technologies management team is about average.
Management Team

Pierre-Henri Benhamou

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
€610K
AGE
63
TENURE
17.3 yrs

David Schilansky

TITLE
Deputy CEO & CFO
COMPENSATION
€457K
AGE
43

Laurent Martin

TITLE
Deputy CEO & Responsible Pharmacist
COMPENSATION
€252K
AGE
51
TENURE
3.9 yrs

Daniel Tassé

TITLE
CEO & Director
AGE
58
TENURE
0.5 yrs

Hugh Sampson

TITLE
Interim Chief Medical Officer
AGE
69
TENURE
3.9 yrs

Sara Sherman

TITLE
Director of Investor Relations & Strategy

Joan Schmidt

TITLE
Chief Legal Officer
AGE
54
TENURE
0.9 yrs

Joe Becker

TITLE
Vice President of Global Corporate Communications

Wence Agbotounou

TITLE
Chief Clinical Trial Officer & Senior VP
TENURE
3 yrs

Pascale Ehouarn

TITLE
Chief Engineering
AGE
44
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the DBV Technologies board of directors in years:

1.5
Average Tenure
63
Average Age
  • The average tenure for the DBV Technologies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Michel de Rosen

TITLE
Non-Executive Chairman
AGE
67
TENURE
0.2 yrs

Pierre-Henri Benhamou

TITLE
Co-Founder & Member of Scientific Advisory Board
COMPENSATION
€610K
AGE
63
TENURE
0.2 yrs

Daniel Tassé

TITLE
CEO & Director
AGE
58
TENURE
0.2 yrs

Hugh Sampson

TITLE
Interim Chief Medical Officer
AGE
69
TENURE
7 yrs

Torbjørn Bjerke

TITLE
Independent Director
COMPENSATION
€83K
AGE
56
TENURE
13.3 yrs

Christophe Dupont

TITLE
Chairman of the Scientific Advisory Board

Claire Giraut

TITLE
Independent Director
COMPENSATION
€90K
AGE
62
TENURE
2.9 yrs

Paul-Henri Lambert

TITLE
Member of the Scientific Advisory Board
AGE
79

Gideon Lack

TITLE
Member of the Scientific Advisory Board

Philippe Eigenmann

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Apr 19 Buy Bpifrance Participations SA Company 08. Apr 19 08. Apr 19 1,247,920 €12.02 €14,999,999
09. Apr 19 Buy Icade Company 22. Oct 18 02. Nov 18 60,000 €34.15 €1,950,772
09. Apr 19 Buy Bpifrance Investissement Company 05. Jun 18 06. Jun 18 28,135 €37.27 €1,047,635
X
Management checks
We assess DBV Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DBV Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DBV News

Simply Wall St News

Why DBV Technologies S.A. (EPA:DBV) Could Be Your Next Investment

(EPA:DBV) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … In the case of DBV, it

Simply Wall St -

How Does Investing In DBV Technologies S.A. (EPA:DBV) Impact The Volatility Of Your Portfolio?

(EPA:DBV), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Is DBV Technologies SA's (EPA:DBV) CEO Paid Enough Relative To Peers?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Pierre-Henri Benhamou's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that DBV Technologies SA has a market cap of €795m, and is paying total annual CEO compensation of €610k.

Simply Wall St -

Analysts Expect Breakeven For DBV Technologies SA (ENXTPA:DBV)

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. … The €1.08b market-cap company announced a latest loss of -€147.69m on 31 December 2017 for its most recent financial year result. … Many investors are wondering the rate at which DBV will turn a profit, with the big question being “when will the company breakeven?”

Simply Wall St -

Where DBV Technologies SA.'s (EPA:DBV) Earnings Growth Stands Against Its Industry

Today I will assess DBV's recent performance announced on 31 December 2017 and weigh these figures against its long-term trend and industry movements. … View our latest analysis for DBV Technologies How Did DBV's Recent Performance Stack Up Against Its Past? … I prefer to use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data.

Simply Wall St -

What Should We Expect From DBV Technologies SA.'s (EPA:DBV) Earnings In The Next Couple Of Years?

DBV Technologies SA.'s (ENXTPA:DBV) most recent earnings update in December 2017 indicated that losses became smaller relative to the prrior year's level - great news for investors Below, I've laid out key numbers on how market analysts perceive DBV Technologies's earnings growth trajectory over the next few years and whether the future looks brighter. … See our latest analysis for DBV Technologies Market analysts' consensus outlook for the upcoming year seems pessimistic, with earnings becoming even more negative, generating -€195.38M in 2019. … The slope of this line is the rate of earnings growth, which in this case is 37.47%.

Simply Wall St -

When Will DBV Technologies SA. (EPA:DBV) Turn A Profit?

They expect the company to post a final loss in 2020, before turning a profit of €68.71M in 2021. … Next Steps: This article is not intended to be a comprehensive analysis on DBV, so if you are interested in understanding the company at a deeper level, take a look at DBV’s company page on Simply Wall St. … Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.

Simply Wall St -

DBV Company Info

Description

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn’s disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Details
Name: DBV Technologies S.A.
DBV
Exchange: ENXTPA
Founded: 2002
€607,475,745
36,116,275
Website: http://www.dbv-technologies.com
Address: DBV Technologies S.A.
177-181 avenue Pierre Brossolette,
Montrouge,
Ile-de-France, 92120,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA DBV Common Stock Euronext Paris FR EUR 29. Mar 2012
OTCPK DBVT.F Common Stock Pink Sheets LLC US USD 29. Mar 2012
DB DBV Common Stock Deutsche Boerse AG DE EUR 29. Mar 2012
LSE 0QAJ Common Stock London Stock Exchange GB EUR 29. Mar 2012
BATS-CHIXE DBVP Common Stock BATS 'Chi-X Europe' GB EUR 29. Mar 2012
NasdaqGS DBVT SPONSORED ADR Nasdaq Global Select US USD 23. Oct 2014
DB DBVA SPONSORED ADR Deutsche Boerse AG DE EUR 23. Oct 2014
Number of employees
Current staff
Staff numbers
315
DBV Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/19 22:11
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/14
Last earnings filing: 2019/04/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.